Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for violations of federal securities laws, impacting investors who sold shares during a specified period, held shares on a record date, or sold shares during a significant transaction involving Bain Capital [1][2][3] Group 1: Lawsuit Details - The lawsuit includes three classes of investors: those who sold shares between October 11, 2023, and August 1, 2024, those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1] - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel, which artificially deflated the stock price [2] - Following the October Offering, Cerevel announced a merger with AbbVie at $45 per share, resulting in significant financial gains for Bain Capital, which acquired shares at a depressed price [3] Group 2: Financial Impact - Bain Capital reportedly received over$120 million from the shares acquired during the October Offering due to the subsequent merger announcement [3] - Investors who suffered losses exceeding $100,000 in Cerevel's securities are encouraged to participate in the lawsuit [4]